Pediapharm Inc. Announces the Launch of Pediapharm Naproxen Suspension in Canada

MONTREAL, QUEBEC--(Marketwired - Feb. 5, 2015) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Pediapharm Inc. ("Pediapharm" or the "Company") (TSX VENTURE:PDP) announced today the launch of Pediapharm Naproxen Suspension seven months after the Company acquired the Canadian rights from Hoffmann-La Roche Limited ("Roche"). As previously announced, Roche retains the Naprosyn™ trademark and retains all product rights to the other oral dosage forms under this brand.

This product, in its suspension form, is only available under prescription (Rx) and is indicated for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. It is also indicated for the relief of minor aches and pains in muscles, bones and joints, mild to moderate pain accompanied by inflammation in musculoskeletal injuries (sprains and strains) and primary dysmenorrhea. The Pediapharm Naproxen Suspension will be competing in a Canadian market valued at $ 76 million (prescription tablets and suspension NSAID-IMS data 2013).

Pediapharm expects that the product will be available to patients in March 2015 as it plans to start shipping products to wholesalers and key retailers in late February 2015. The introduction of Pediapharm Naproxen Suspension will put an end to the Special Access Programme (SAP) initiated by Health Canada on July 24, 2014.

"We are very enthusiastic about this important milestone" said Sylvain Chretien, President and CEO of Pediapharm. "We expect Pediapharm Naproxen Suspension, our first product acquisition, to generate an excellent return on investment. This product launch supports our strategy to increase revenue in a short period of time" concluded Mr. Chretien.

"Naproxen helps to alleviate joint pain and inflammation in juvenile arthritis; however, children can have difficulty swallowing pills, and liquid naproxen provides another way to administer this treatment to them," said Dr. Rosie Scuccimarri, Chair of the Pediatric Committee of the Canadian Rheumatology Association (CRA). "

"The re-introduction of naproxen suspension on the Canadian market is an excellent example of how stakeholders quickly aligned their interests", said Benoît Hébert, Pediapharm's Vice President of Business Development and Licensing. "We're thankful for the collaboration from Roche and the support from CRA members, The Arthritis Society, the Ontario Rheumatology Association and Health Canada's SAP Office throughout the process".

Naprosyn™ is a trademark of Hoffmann-La Roche Limited.

About the Canadian Rheumatology Association

The Canadian Rheumatology Association (CRA) is the national professional association for Canadian rheumatologists.

The mission of the CRA is to represent Canadian Rheumatologists and promote the pursuit of excellence in Arthritis Care, Education and Research. The CRA, re-established in 1993, in its current iteration, has organizational roots reaching back to the Canadian Rheumatic Disease Association (1936) and Canadian Rheumatism Association (1946). The goals of the association include advancing professional camaraderie, research and training to improve the health of Canadians with rheumatic diseases. Today, the CRA comprises over 500 members throughout all 10 provinces and territories.

Since its inception, the CRA has promoted and advanced the field of rheumatology by organizing networking, training and education opportunities for clinicians, students, allied health professionals and researchers. More recently the CRA has become involved in the promotion and coordination of funding for important rheumatology research (CIORA).

The CRA's vision is to improve the care and quality of life of patients suffering from rheumatic conditions. According to a Health Canada study, an estimated 1 in 6 Canadians has some type of arthritis; two thirds of affected Canadians are under the age of 65 years. Arthritis and rheumatic diseases not only have a profound effect on patient quality of life, but also accounts for an estimated $33 billion burden on Canadians.

About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world.

FORWARD LOOKING STATEMENTS FOR PEDIAPHARM

This news release contains forward-looking statements and other statements that are not historical. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to vary materially from target results and the results or events predicted in these forward-looking statements. As a result, investors are cautioned not to place undue reliance on these forward-looking statements.

The forward-looking statements contained in this news release are made as of the date of this release. Except as required by applicable law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking information reflects the current expectations or belief of the Corporation based on information currently available and such information is subject to a number of assumptions, risks and uncertainties described in details at pp. 35 to 41 of the Management Information Circular of Chelsea Acquisition Corporation dated November 12, 2013 available on SEDAR at www.sedar.com and other risks associated with being a specialty pharmaceutical company.

For more information about Pediapharm or its products, please visit www.pedia-pharm.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.